High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme

Pathology Research and Practice

Volumn 211, Issue 8, 2015, Pages 596-600

  Liu, Bin ^a,b   Pang, Bo ^c   Liu, Huajie ^a   Arakawa, Yoshiki ^b   Zhang, Rui ^a   Feng, Bin ^a   Zhong, Peng ^a   Murata, Daiki ^b   Fan, Haitao ^a   Xin, Tao ^a   Zhao, Guangyu ^a   Liu, Wei ^a   Guo, Hua ^a   Luan, Liming ^a   Xu, Shangchen ^a   Miyamoto, Susumu ^b   Pang, Qi ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Glioblastoma multiforme; High mobility group A1; Isocitrate dehydrogenase 1 mutation; Progression free survival time; Recurrence

Indexed keywords

HIGH MOBILITY GROUP A1A PROTEIN; ISOCITRATE DEHYDROGENASE 1; HIGH MOBILITY GROUP A PROTEIN; ISOCITRATE DEHYDROGENASE;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CRANIOTOMY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HMGA1 GENE; HUMAN; HUMAN TISSUE; IDH 1 GENE; IMMUNOHISTOCHEMISTRY; MALE; POINT MUTATION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; UPREGULATION; BRAIN TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; TUMOR RECURRENCE;

ADULT; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HMGA PROTEINS; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL;

EID: 84983134948     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2015.05.004     Document Type: Article

References (24)

1. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114(2):97-109. (Epub 2007/07/10).
2. Meyer M.A. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359(17):1850. (author reply Epub 2008/10/24).
3. Wen P.Y., Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359(5):492-507. (Epub 2008/08/02).
4. Liu B., Pang B., Hou X., Fan H., Liang N., Zheng S., et al. Expression of high-mobility group AT-hook protein 2 and its prognostic significance in malignant gliomas. Hum. Pathol. 2014, 45(8):1752-1758. (Epub 2014/06/18).
5. Shen S.H., Kwan A.L., Chen Y.Y., Wang Z.X. Effect of silencing HIF-1alpha on proliferation, invasion and migration of glioblastoma U87 cells. Neurol. Sci. 2013, 34(3):365-371. (Epub 2012/03/29).
6. Grasser K.D. Chromatin-associated HMGA and HMGB proteins: versatile co-regulators of DNA-dependent processes. Plant Mol. Biol. 2003, 53(3):281-295. (Epub 2004/01/31).
7. Pang B., Fan H., Zhang I.Y., Liu B., Feng B., Meng L., et al. HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis. J. Neuro-oncol. 2012, 106(3):543-549. (Epub 2011/10/11).
8. Reeves R., Nissen M.S. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J. Biol. Chem. 1990, 265(15):8573-8582. (Epub 1990/05/25).
9. Lovell-Badge R. Developmental genetics. Living with bad architecture. Nature 1995, 376(6543):725-726. (Epub 1995/08/31).
10. Chiappetta G., Avantaggiato V., Visconti R., Fedele M., Battista S., Trapasso F., et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996, 13(11):2439-2446. (Epub 1996/12/05).
11. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001, 277(1/2):63-81. (Epub 2001/10/17).
12. Pegoraro S., Ros G., Piazza S., Sommaggio R., Ciani Y., Rosato A., et al. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget 2013, 4(8):1293-1308. Epub 2013/08/16.
13. Liang L., Li X., Zhang X., Lv Z., He G., Zhao W., et al. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2. Gastroenterology 2013, 144(3):624 e4-635 e4. (Epub 2012/12/04).
14. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321(5897):1807-1812. (Epub 2008/09/06).
15. Hartmann C., Hentschel B., Simon M., Westphal M., Schackert G., Tonn J.C., et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin. Cancer Res. 2013, 19(18):5146-5157. (Epub 2013/08/07).
16. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009, 118(4):469-474. (Epub 2009/06/26).
17. Asha U., Mahadevan A., Sathiyabama D., Ravindra T., Sagar B.K., Bhat D.I., et al. Lack of IDH1 mutation in astroblastomas suggests putative origin from ependymoglial cells?. Neuropathology 2015, (Epub 2015/03/20).
18. Johannessen A.L., Torp S.H. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol. Oncol. Res. 2006, 12(3):143-147. (Epub 2006/09/26).
19. Qu Y., Wang Y., Ma J., Zhang Y., Meng N., Li H., et al. Overexpression of high mobility group A1 protein in human uveal melanomas: implication for prognosis. PLOS ONE 2013, 8(7):e68724. (Epub 2013/08/13).
20. Huso T.H., Resar L.M. The high mobility group A1 molecular switch: turning on cancer - can we turn it off?. Exp. Opin. Ther. Targets 2014, 18(5):541-553. (Epub 2014/04/02).
21. Zhang Z., Wang Q., Chen F., Liu J. Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer. Tumour Biol. 2014, (Epub 2014/10/26).
22. Chieffi P. New prognostic markers and potential therapeutic targets in human testicular germ cell tumors. Curr. Med. Chem. 2011, 18(33):5033-5040. (Epub 2011/11/05).
23. Hristov A.C., Cope L., Di Cello F., Reyes M.D., Singh M., Hillion J.A., et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod. Pathol. 2010, 23(1):98-104. (Epub 2009/10/13).
24. Juratli T.A., Kirsch M., Geiger K., Klink B., Leipnitz E., Pinzer T., et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J. Neuro-oncol. 2012, 110(3):325-333. (Epub 2012/09/28).